<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Asthma</journal-id><journal-id journal-id-type="publisher-id">ljas</journal-id><journal-title>The Journal of Asthma </journal-title><issn pub-type="ppub">0277-0903</issn><issn pub-type="epub">1532-4303</issn><publisher><publisher-name>Informa Healthcare</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17994402</article-id><article-id pub-id-type="pmc">2409177</article-id><article-id pub-id-type="doi">10.1080/02770900701595667</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>An Evaluation of Levalbuterol HFA in the Prevention of Exercise-Induced Bronchospasm</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pearlman</surname><given-names>D.S.</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="au1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Rees</surname><given-names>William</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schaefer</surname><given-names>Kendyl</given-names></name><degrees>M.Sc.</degrees><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Holly</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Andrews</surname><given-names>William T.</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="au3">3</xref></contrib></contrib-group><aff id="au1"><label>1</label>Colorado Allergy and Asthma Centers, P.C., Denver, Colorado, U.S.A.</aff><aff id="au2"><label>2</label>PI-Coor Clinical Research LLC, Burke, Virginia, U.S.A.</aff><aff id="au3"><label>3</label>Sepracor Inc., Marlborough, Massachusetts, U.S.A.</aff><author-notes><fn><p>Study support provided by Sepracor Inc., Marlborough, MA.</p></fn><fn><p>D.S.P. and W.R. were investigators who participated in this study. K.S., H.H., and W.T.A. are Sepracor employees.</p></fn><corresp id="cor1"><label>*</label>Corresponding author: Dr. David S. Pearlman, Colorado Allergy and Asthma Centers, P.C., 125 Rampart Way, Suite 150, Denver, Colorado 80230; E-mail: <email>ds.pearlman@coloradoallergy.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>8</day><month>11</month><year>2007</year></pub-date><volume>44</volume><issue>9</issue><fpage>729</fpage><lpage>733</lpage><permissions><copyright-statement>© 2007 Informa Healthcare USA, Inc.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="3356" xml_f="3366" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3377" xml_f="3459" txt_i="22" txt_f="104">Exercise-induced bronchospasm (EIB) affects up to 90% of all patients with asthma.</offsets></p></sec><sec><title><offsets xml_i="3481" xml_f="3490" txt_i="106" txt_f="115">Objective</offsets></title><p><offsets xml_i="3501" xml_f="3704" txt_i="116" txt_f="319">This study evaluated the ability of levalbuterol hydrofluoroalkane (HFA) 90 μg (two actuations of 45 μg) administered via metered dose inhaler (MDI) to protect against EIB in mild-to-moderate asthmatics.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3745" xml_f="3752" txt_i="321" txt_f="328">Methods</offsets></title><p><offsets xml_i="3763" xml_f="3868" txt_i="329" txt_f="434">This was a randomized, double-blind, placebo-controlled, two-way cross-over study. Patients with asthma (</offsets><italic><offsets xml_i="3876" xml_f="3877" txt_i="434" txt_f="435">n</offsets></italic><offsets xml_i="3886" xml_f="4005" txt_i="435" txt_f="554"> = 15) were ≥18 years, had a ≥6-month history of EIB, ≥70% baseline predicted forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="4010" xml_f="4011" txt_i="554" txt_f="555">1</offsets></sub><offsets xml_i="4017" xml_f="4052" txt_i="555" txt_f="590">), and a 20% to 50% decrease in FEV</offsets><sub><offsets xml_i="4057" xml_f="4058" txt_i="590" txt_f="591">1</offsets></sub><offsets xml_i="4064" xml_f="4450" txt_i="591" txt_f="977"> after treadmill exercise challenge using single-blind placebo MDI. Levalbuterol or placebo was self-administered 30 minutes before exercise. Treatment sequences were separated by a 3-to 7-day washout period. Spirometry was performed predose, 20 minutes postdose/pre-exercise, and 5, 10, 15, 30, and 60 minutes post-exercise. The primary endpoint was the maximum percent decrease in FEV</offsets><sub><offsets xml_i="4455" xml_f="4456" txt_i="977" txt_f="978">1</offsets></sub><offsets xml_i="4462" xml_f="4565" txt_i="978" txt_f="1081"> from baseline (postdose/pre-exercise). The percentage of protected (≤20% decrease in post-exercise FEV</offsets><sub><offsets xml_i="4570" xml_f="4571" txt_i="1081" txt_f="1082">1</offsets></sub><offsets xml_i="4577" xml_f="4606" txt_i="1082" txt_f="1111">) patients was also assessed.</offsets></p></sec><sec><title><offsets xml_i="4628" xml_f="4635" txt_i="1113" txt_f="1120">Results</offsets></title><p><offsets xml_i="4646" xml_f="4730" txt_i="1121" txt_f="1205">Levalbuterol had significantly smaller maximum percent post-exercise decrease in FEV</offsets><sub><offsets xml_i="4735" xml_f="4736" txt_i="1205" txt_f="1206">1</offsets></sub><offsets xml_i="4742" xml_f="4912" txt_i="1206" txt_f="1373"> compared with placebo (LS mean ± SE; −4.8% ± 2.8% versus −22.5% ± 2.8%, respectively). For levalbuterol, 14/15 (93.3%) patients had &lt;20% decrease in post-exercise FEV</offsets><sub><offsets xml_i="4917" xml_f="4918" txt_i="1373" txt_f="1374">1</offsets></sub><offsets xml_i="4924" xml_f="4965" txt_i="1374" txt_f="1415"> compared with 8/15 (53.3%) for placebo (</offsets><italic><offsets xml_i="4973" xml_f="4974" txt_i="1415" txt_f="1416">p</offsets></italic><offsets xml_i="4983" xml_f="5024" txt_i="1416" txt_f="1457"> = 0.0143). Treatment was well tolerated.</offsets></p></sec><sec><title><offsets xml_i="5046" xml_f="5056" txt_i="1459" txt_f="1469">Conclusion</offsets></title><p><offsets xml_i="5067" xml_f="5265" txt_i="1470" txt_f="1668">Levalbuterol HFA MDI (90 μg) administered 30 minutes before exercise was significantly more effective than placebo in protecting against EIB after a single exercise challenge and was well tolerated.</offsets></p></sec><sec><title><offsets xml_i="5287" xml_f="5308" txt_i="1670" txt_f="1691">Clinical Implications</offsets></title><p><offsets xml_i="5319" xml_f="5430" txt_i="1692" txt_f="1803">Levalbuterol HFA MDI when administered before exercise was effective in protecting adults with asthma from EIB.</offsets></p></sec></abstract><kwd-group><kwd>levalbuterol HFA</kwd><kwd>exercise-induced bronchospasm</kwd><kwd>β<sub>2</sub>-agonist</kwd><kwd>efficacy</kwd><kwd>metered dose inhaler (MDI)</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="5670" xml_f="5682" txt_i="1812" txt_f="1824">Introduction</offsets></title><p><offsets xml_i="5693" xml_f="5863" txt_i="1825" txt_f="1995">Exercise-induced bronchospasm (EIB) is a common condition occurring in up to 90% of patients with asthma and in up to 10% of patients that are not known to be asthmatic (</offsets><xref ref-type="bibr" rid="b1"><offsets xml_i="5894" xml_f="5895" txt_i="1995" txt_f="1996">1</offsets></xref><offsets xml_i="5902" xml_f="5904" txt_i="1996" txt_f="1998">, </offsets><xref ref-type="bibr" rid="b2"><offsets xml_i="5935" xml_f="5936" txt_i="1998" txt_f="1999">2</offsets></xref><offsets xml_i="5943" xml_f="6148" txt_i="1999" txt_f="2204">). EIB is an acute transient airway narrowing that occurs sometimes during or very often after exercise. It is thought to be initiated by abrupt changes in airway temperature and humidity during exercise (</offsets><xref ref-type="bibr" rid="b1"><offsets xml_i="6179" xml_f="6180" txt_i="2204" txt_f="2205">1</offsets></xref><offsets xml_i="6187" xml_f="6246" txt_i="2205" txt_f="2264">). It is particularly common in children and young adults (</offsets><xref ref-type="bibr" rid="b3"><offsets xml_i="6277" xml_f="6278" txt_i="2264" txt_f="2265">3</offsets></xref><offsets xml_i="6285" xml_f="6413" txt_i="2265" txt_f="2393">), most likely due to their higher physical activity. EIB often results in affected persons withdrawing from physical activity (</offsets><xref ref-type="bibr" rid="b4"><offsets xml_i="6444" xml_f="6445" txt_i="2393" txt_f="2394">4</offsets></xref><offsets xml_i="6452" xml_f="6453" txt_i="2394" txt_f="2395">–</offsets><xref ref-type="bibr" rid="b6"><offsets xml_i="6484" xml_f="6485" txt_i="2395" txt_f="2396">6</offsets></xref><offsets xml_i="6492" xml_f="6593" txt_i="2396" txt_f="2497">). The current asthma treatment guidelines recommend pre-treating EIB by administering short-acting β</offsets><sub><offsets xml_i="6598" xml_f="6599" txt_i="2497" txt_f="2498">2</offsets></sub><offsets xml_i="6605" xml_f="6684" txt_i="2498" txt_f="2577">-agonists shortly before exercise, which can protect over 80% of the patients (</offsets><xref ref-type="bibr" rid="b7"><offsets xml_i="6715" xml_f="6716" txt_i="2577" txt_f="2578">7</offsets></xref><offsets xml_i="6723" xml_f="6725" txt_i="2578" txt_f="2580">).</offsets></p><p><offsets xml_i="6732" xml_f="6770" txt_i="2581" txt_f="2619">Two commonly prescribed short-acting β</offsets><sub><offsets xml_i="6775" xml_f="6776" txt_i="2619" txt_f="2620">2</offsets></sub><offsets xml_i="6782" xml_f="7042" txt_i="2620" txt_f="2880">-agonists used for treating asthma are racemic albuterol and levalbuterol. Racemic albuterol is a 1:1 mixture of (R)- and (S)-albuterol. The (R)-albuterol enantiomer is responsible for the bronchoprotective and bronchodilatory properties of racemic albuterol (</offsets><xref ref-type="bibr" rid="b8"><offsets xml_i="7073" xml_f="7074" txt_i="2880" txt_f="2881">8</offsets></xref><offsets xml_i="7081" xml_f="7083" txt_i="2881" txt_f="2883">, </offsets><xref ref-type="bibr" rid="b9"><offsets xml_i="7114" xml_f="7115" txt_i="2883" txt_f="2884">9</offsets></xref><offsets xml_i="7122" xml_f="7430" txt_i="2884" txt_f="3192">). Levalbuterol is the (R)-albuterol enantiomer and is available as a hydrofluoroalkane (HFA) metered dose inhaler (MDI) or as a solution for nebulization. Pre-clinical studies suggest that (S)-albuterol may be pro-inflammatory and pro-constrictive and may attenuate the beneficial effects of (R)-albuterol (</offsets><xref ref-type="bibr" rid="b10"><offsets xml_i="7462" xml_f="7464" txt_i="3192" txt_f="3194">10</offsets></xref><offsets xml_i="7471" xml_f="7552" txt_i="3194" txt_f="3275">). The clinical relevance of these data for the treatment of asthma is not clear.</offsets></p><p><offsets xml_i="7559" xml_f="7654" txt_i="3276" txt_f="3371">Several studies have demonstrated the ability of racemic albuterol MDI to protect against EIB (</offsets><xref ref-type="bibr" rid="b11"><offsets xml_i="7686" xml_f="7688" txt_i="3371" txt_f="3373">11</offsets></xref><offsets xml_i="7695" xml_f="7696" txt_i="3373" txt_f="3374">–</offsets><xref ref-type="bibr" rid="b15"><offsets xml_i="7728" xml_f="7730" txt_i="3374" txt_f="3376">15</offsets></xref><offsets xml_i="7737" xml_f="7968" txt_i="3376" txt_f="3607">). Although the FDA has not approved levalbuterol HFA MDI to treat EIB, we were interested in evaluating the protective effect of levalbuterol in asthmatics. This is the first reported study to investigate and describe that effect.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="8009" xml_f="8016" txt_i="3609" txt_f="3616">Methods</offsets></title><sec><title><offsets xml_i="8036" xml_f="8048" txt_i="3617" txt_f="3629">Study Design</offsets></title><p><offsets xml_i="8059" xml_f="8548" txt_i="3630" txt_f="4119">This was a randomized, double-blind, placebo-controlled, multicenter, two-way cross-over study designed to evaluate the efficacy of levalbuterol HFA MDI (90 μg; two actuations of 45 μg each) versus placebo in subjects with asthma 18 years of age and older with EIB. The study was conducted according to the principles established by the Declaration of Helsinki. The appropriate Institutional Review Boards approved the protocol, and written informed consent was obtained from the patients.</offsets></p></sec><sec><title><offsets xml_i="8570" xml_f="8584" txt_i="4121" txt_f="4135">Study Patients</offsets></title><p><offsets xml_i="8595" xml_f="8718" txt_i="4136" txt_f="4259">Eligible patients were required to be ≥18 years of age with stable asthma; have a forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="8723" xml_f="8724" txt_i="4259" txt_f="4260">1</offsets></sub><offsets xml_i="8730" xml_f="8772" txt_i="4260" txt_f="4302">) ≥70% of predicted, and have been using β</offsets><sub><offsets xml_i="8777" xml_f="8778" txt_i="4302" txt_f="4303">2</offsets></sub><offsets xml_i="8784" xml_f="9016" txt_i="4303" txt_f="4535">-adrenergic agonists, anti-asthma, anti-inflammatory medication, or over-the-counter asthma medication for at least 6 months. Patients were required to have a documented history of EIB for a minimum of 6 months and a decrease in FEV</offsets><sub><offsets xml_i="9021" xml_f="9022" txt_i="4535" txt_f="4536">1</offsets></sub><offsets xml_i="9028" xml_f="9264" txt_i="4536" txt_f="4772"> of at least 20% but no more than 50% after a dose of single blind placebo MDI (HFA-134a propellant containing ethanol and oleic acid; two actuations) and a baseline exercise challenge. One patient with a maximum percent decrease in FEV</offsets><sub><offsets xml_i="9269" xml_f="9270" txt_i="4772" txt_f="4773">1</offsets></sub><offsets xml_i="9276" xml_f="9924" txt_i="4773" txt_f="5421"> of 19% was included in the study. Patients were ineligible if they were diagnosed with life-threatening asthma (intubation, hypercapnia, respiratory arrest, hypoxic seizures) within 12 months before the first study visit. They were also not eligible if they had been hospitalized with asthma within 4 weeks of the first visit or had a significant upper or lower respiratory infection 3 weeks before the first study visit. Patients were excluded if they had a documented history of bronchopulmonary aspergillosis or allergic alveolitis or had greater than 10-pack-year history of smoking or tobacco product use within 6 months of the initial visit.</offsets></p><p><offsets xml_i="9931" xml_f="10553" txt_i="5422" txt_f="6044">Medications that were disallowed during the entire study period included parenteral or oral corticosteroids, all adrenergic bronchodilators (except the study medication), nonprescription asthma medication, and ipratropium bromide. Leukotriene inhibitors and low to moderate doses (≤660 μg fluticasone/day or ≤800 μg beclomethasone/day) of inhaled corticosteroids were allowed provided the patient was maintained on a stable dose 30 days before visit 1. Inhaled corticosteroids were withheld for 10 hours before each study visit. Antihistamines were also allowed but had to be withheld for 48 hours before each study visit.</offsets></p></sec><sec><title><offsets xml_i="10575" xml_f="10589" txt_i="6046" txt_f="6060">Study Protocol</offsets></title><p><offsets xml_i="10600" xml_f="11542" txt_i="6061" txt_f="7003">The study consisted of three visits, each separated by 3 to 7 days. At the screening visit (visit 1), all baseline values were obtained. This included an exercise challenge to confirm the diagnosis of EIB per protocol limits. At visit 2, patients were randomly assigned to one of two treatments (levalbuterol HFA MDI [90 μg, two actuations of 45 μg each] or placebo [HFA-134a propellant containing ethanol and oleic acid; two actuations]). Randomization occurred separately within each site using permutated blocks of four. At visit 3 patients were crossed-over to the alternate treatment. At visit 1, subjects received an open-label levalbuterol HFA MDI to be used as rescue medication during the study. Rescue medication was used as-needed except on the day of a clinic visit when it was withheld for at least 8 hours before the visit. Patients also received medical event calendars for monitoring adverse events and concomitant medication.</offsets></p><p><offsets xml_i="11549" xml_f="11632" txt_i="7004" txt_f="7087">A standard exercise challenge on a treadmill was performed at 30 minutes postdose (</offsets><xref ref-type="bibr" rid="b16"><offsets xml_i="11664" xml_f="11666" txt_i="7087" txt_f="7089">16</offsets></xref><offsets xml_i="11673" xml_f="12759" txt_i="7089" txt_f="8175">). During the exercise challenge, the gradient and speed of the treadmill were adjusted at 1-minute intervals to achieve at least 85% of the subject's maximum predicted heart rate (calculated as 220 minus the patient's age). At the qualifying exercise challenge (visit 1), the settings for the treadmill rate and incline at each time interval were recorded. These settings were used for the initial settings at each subsequent exercise challenge with minor adjustments to maintain the subject's target maximum heart rate (85% of maximum). The exercise challenge was concluded when patients maintained the target heart rate for a minimum of 4 minutes. The subject could also stop the test at any time. To control for temperature and humidity of the inspired air during the exercise challenge, subjects inspired compressed dry air at room temperature through a Hans Rudolph Nasal and Mouth Breathing Face Mask with a T-shape configuration and a Two-Way Non-Rebreathing Valve (Hans Rudolf, Inc., Kansas City, Missouri, USA). The temperature of the room was maintained between 68°F to 77°F.</offsets></p><p><offsets xml_i="12766" xml_f="13436" txt_i="8176" txt_f="8846">Before the exercise challenge, patients self-administered (two actuations) single-blind placebo MDI (visit 1) or randomized double-blind medication (visits 2 and 3). The MDI was primed (four test sprays) before use by study personnel before dispensing and the subject was instructed on its proper use. Study personnel monitored proper administration of the drug. Spirometry was performed predose/pre-exercise, 20 minutes postdose/pre-exercise (e.g., 10 minutes before exercise), and at 5, 10, 15, 30, and 60 minutes post-exercise (±1 minute). After 60 minutes, spirometry measurements continued every 15 minutes until the subject returned to within 5% of the predose FEV</offsets><sub><offsets xml_i="13441" xml_f="13442" txt_i="8846" txt_f="8847">1</offsets></sub><offsets xml_i="13448" xml_f="13470" txt_i="8847" txt_f="8869">. If the subject's FEV</offsets><sub><offsets xml_i="13475" xml_f="13476" txt_i="8869" txt_f="8870">1</offsets></sub><offsets xml_i="13482" xml_f="13616" txt_i="8870" txt_f="9004"> values did not return to the pre-exercise level within 4 hours, the visit was concluded at the Investigator's discretion. A final FEV</offsets><sub><offsets xml_i="13621" xml_f="13622" txt_i="9004" txt_f="9005">1</offsets></sub><offsets xml_i="13628" xml_f="13659" txt_i="9005" txt_f="9036"> was measured before discharge.</offsets></p><p><offsets xml_i="13666" xml_f="13951" txt_i="9037" txt_f="9322">Heart rate was monitored each minute during exercise. Vital signs were measured before and immediately after exercise challenge, before the 30- and 60-minute spirometry measurements, and at discharge. Adverse events were collected from the time of informed consent to the end of study.</offsets></p><p><offsets xml_i="13958" xml_f="14018" txt_i="9323" txt_f="9383">The primary endpoint was the maximum percent decrease in FEV</offsets><sub><offsets xml_i="14023" xml_f="14024" txt_i="9383" txt_f="9384">1</offsets></sub><offsets xml_i="14030" xml_f="14068" txt_i="9384" txt_f="9422"> from visit postdose/pre-challenge FEV</offsets><sub><offsets xml_i="14073" xml_f="14074" txt_i="9422" txt_f="9423">1</offsets></sub><offsets xml_i="14080" xml_f="14126" txt_i="9423" txt_f="9469">. Secondary endpoints included the time to FEV</offsets><sub><offsets xml_i="14131" xml_f="14132" txt_i="9469" txt_f="9470">1</offsets></sub><offsets xml_i="14138" xml_f="14233" txt_i="9470" txt_f="9565"> recovery after exercise challenge (defined as the amount of time post-challenge needed for FEV</offsets><sub><offsets xml_i="14238" xml_f="14239" txt_i="9565" txt_f="9566">1</offsets></sub><offsets xml_i="14245" xml_f="14337" txt_i="9566" txt_f="9658"> to return to within 5% of the postdose/pre-challenge value), the mean percent change in FEV</offsets><sub><offsets xml_i="14342" xml_f="14343" txt_i="9658" txt_f="9659">1</offsets></sub><offsets xml_i="14349" xml_f="14543" txt_i="9659" txt_f="9853"> from visit predose to postdose/pre-challenge to post exercise, and the number of protected/unprotected patients. Protected patients were defined as those who had less than a 20% decrease in FEV</offsets><sub><offsets xml_i="14548" xml_f="14549" txt_i="9853" txt_f="9854">1</offsets></sub><offsets xml_i="14555" xml_f="14688" txt_i="9854" txt_f="9987">. These values were based on guidelines (USDHHS Guidance for Industry) that consider patients with a greater than 20% decrease in FEV</offsets><sub><offsets xml_i="14693" xml_f="14694" txt_i="9987" txt_f="9988">1</offsets></sub><offsets xml_i="14700" xml_f="14759" txt_i="9988" txt_f="10047"> after exercise challenge as not being protected from EIB (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="14791" xml_f="14793" txt_i="10047" txt_f="10049">17</offsets></xref><offsets xml_i="14800" xml_f="14908" txt_i="10049" txt_f="10157">). Analyses of protection at other levels (15% and 10%) considered by other investigators to be protective (</offsets><xref ref-type="bibr" rid="b16"><offsets xml_i="14940" xml_f="14942" txt_i="10157" txt_f="10159">16</offsets></xref><offsets xml_i="14949" xml_f="14951" txt_i="10159" txt_f="10161">, </offsets><xref ref-type="bibr" rid="b18"><offsets xml_i="14983" xml_f="14985" txt_i="10161" txt_f="10163">18</offsets></xref><offsets xml_i="14992" xml_f="15071" txt_i="10163" txt_f="10242">) were also analyzed. Safety endpoints included adverse events and vital signs.</offsets></p></sec><sec><title><offsets xml_i="15093" xml_f="15113" txt_i="10244" txt_f="10264">Statistical Analysis</offsets></title><p><offsets xml_i="15124" xml_f="15388" txt_i="10265" txt_f="10529">Assuming a within-subject standard deviation of 12 percentage points and based on a two-tailed test with α = 0.05, a sample size of 14 subjects was determined to provide at least 80% power to detect a difference of 10% points in the maximum percent decrease in FEV</offsets><sub><offsets xml_i="15393" xml_f="15394" txt_i="10529" txt_f="10530">1</offsets></sub><offsets xml_i="15400" xml_f="15665" txt_i="10530" txt_f="10795"> from visit postdose/pre-challenge between the two treatment groups. The intent-to-treat (ITT) population consisted of all randomized subjects who received at least one dose of study medication. All efficacy and safety analyses were performed on the ITT population.</offsets></p><p><offsets xml_i="15672" xml_f="15717" txt_i="10796" txt_f="10841">The primary endpoint, the maximum percent FEV</offsets><sub><offsets xml_i="15722" xml_f="15723" txt_i="10841" txt_f="10842">1</offsets></sub><offsets xml_i="15729" xml_f="15856" txt_i="10842" txt_f="10969"> decrease from visit postdose/pre-challenge, was analyzed using a mixed model analysis of variance with the maximum percent FEV</offsets><sub><offsets xml_i="15861" xml_f="15862" txt_i="10969" txt_f="10970">1</offsets></sub><offsets xml_i="15868" xml_f="15964" txt_i="10970" txt_f="11066"> decrease as the dependent variable, sequence, treatment, period, and postdose/pre-challenge FEV</offsets><sub><offsets xml_i="15969" xml_f="15970" txt_i="11066" txt_f="11067">1</offsets></sub><offsets xml_i="15976" xml_f="16027" txt_i="11067" txt_f="11118"> as fixed effects, and patient as a random effect (</offsets><xref ref-type="bibr" rid="b19"><offsets xml_i="16059" xml_f="16061" txt_i="11118" txt_f="11120">19</offsets></xref><offsets xml_i="16068" xml_f="16070" txt_i="11120" txt_f="11122">, </offsets><xref ref-type="bibr" rid="b20"><offsets xml_i="16102" xml_f="16104" txt_i="11122" txt_f="11124">20</offsets></xref><offsets xml_i="16111" xml_f="16129" txt_i="11124" txt_f="11142">). The time to FEV</offsets><sub><offsets xml_i="16134" xml_f="16135" txt_i="11142" txt_f="11143">1</offsets></sub><offsets xml_i="16141" xml_f="16243" txt_i="11143" txt_f="11245"> recovery and the number of subjects with less than 10%, 10% to 20%, and more than 20% decrease in FEV</offsets><sub><offsets xml_i="16248" xml_f="16249" txt_i="11245" txt_f="11246">1</offsets></sub><offsets xml_i="16255" xml_f="16462" txt_i="11246" txt_f="11453"> were summarized by treatment. Other secondary endpoints were analyzed using the same mixed model as the primary endpoint. Percent change from pre-dose and visit predose/post-challenge was summarized for FEV</offsets><sub><offsets xml_i="16467" xml_f="16468" txt_i="11453" txt_f="11454">1</offsets></sub><offsets xml_i="16474" xml_f="16607" txt_i="11454" txt_f="11587"> over time by treatment. The frequency of rescue medication and percent of subjects with adverse events were summarized by treatment.</offsets></p></sec></sec><sec><title><offsets xml_i="16635" xml_f="16642" txt_i="11590" txt_f="11597">Results</offsets></title><p><offsets xml_i="16653" xml_f="16832" txt_i="11598" txt_f="11777">Of 23 patients screened for the study, 15 met the protocol criteria and were randomized to treatment and all 15 completed the study. The mean age was 30.5 years and the majority (</offsets><italic><offsets xml_i="16840" xml_f="16841" txt_i="11777" txt_f="11778">n</offsets></italic><offsets xml_i="16850" xml_f="16868" txt_i="11778" txt_f="11796"> = 13) were male (</offsets><xref ref-type="table" rid="tbl1"><offsets xml_i="16902" xml_f="16909" txt_i="11796" txt_f="11803">Table 1</offsets></xref><offsets xml_i="16916" xml_f="16962" txt_i="11803" txt_f="11849">). Patients had mild-moderate asthma (mean FEV</offsets><sub><offsets xml_i="16967" xml_f="16968" txt_i="11849" txt_f="11850">1</offsets></sub><offsets xml_i="16974" xml_f="17093" txt_i="11850" txt_f="11969"> 86% of predicted), and all had documented EIB. At study entry, 5/15 (33%) of patients were on inhaled corticosteroids.</offsets></p><table-wrap id="tbl1" position="float"><label><offsets xml_i="17143" xml_f="17150" txt_i="11970" txt_f="11977">Table 1</offsets></label><caption><p><offsets xml_i="17170" xml_f="17212" txt_i="11977" txt_f="12019">Demographics and baseline characteristics.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th align="right" rowspan="1" colspan="1"><offsets xml_i="17349" xml_f="17365" txt_i="12020" txt_f="12036">ITT population (</offsets><italic><offsets xml_i="17373" xml_f="17374" txt_i="12036" txt_f="12037">n</offsets></italic><offsets xml_i="17383" xml_f="17389" txt_i="12037" txt_f="12043"> = 15)</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17459" xml_f="17477" txt_i="12043" txt_f="12061">Age, yr, mean (SD)</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="17524" xml_f="17534" txt_i="12062" txt_f="12072">30.5 (9.0)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17589" xml_f="17595" txt_i="12073" txt_f="12079">Male, </offsets><italic><offsets xml_i="17603" xml_f="17604" txt_i="12079" txt_f="12080">n</offsets></italic><offsets xml_i="17613" xml_f="17617" txt_i="12080" txt_f="12084"> (%)</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="17664" xml_f="17673" txt_i="12085" txt_f="12094">13 (86.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17728" xml_f="17734" txt_i="12095" txt_f="12101">Race, </offsets><italic><offsets xml_i="17742" xml_f="17743" txt_i="12101" txt_f="12102">n</offsets></italic><offsets xml_i="17752" xml_f="17756" txt_i="12102" txt_f="12106"> (%)</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17844" xml_f="17854" txt_i="12108" txt_f="12118"> Caucasian</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="17901" xml_f="17909" txt_i="12119" txt_f="12127">15 (100)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17964" xml_f="17967" txt_i="12128" txt_f="12131">FEV</offsets><sub><offsets xml_i="17972" xml_f="17973" txt_i="12131" txt_f="12132">1</offsets></sub><offsets xml_i="17979" xml_f="17995" txt_i="12132" txt_f="12148">, (L), mean (SD)</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="18042" xml_f="18051" txt_i="12149" txt_f="12158">3.8 (0.6)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18106" xml_f="18121" txt_i="12159" txt_f="12174">% Predicted FEV</offsets><sub><offsets xml_i="18126" xml_f="18127" txt_i="12174" txt_f="12175">1</offsets></sub><offsets xml_i="18133" xml_f="18144" txt_i="12175" txt_f="12186">, mean (SD)</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="18191" xml_f="18201" txt_i="12187" txt_f="12197">86.5 (9.2)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18256" xml_f="18281" txt_i="12198" txt_f="12223">Maximum % decrease in FEV</offsets><sub><offsets xml_i="18286" xml_f="18287" txt_i="12223" txt_f="12224">1</offsets></sub><offsets xml_i="18293" xml_f="18340" txt_i="12224" txt_f="12271"> postdose/pre-challenge at screening, mean (SD)</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="18387" xml_f="18398" txt_i="12272" txt_f="12283">−26.5 (7.0)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18453" xml_f="18486" txt_i="12284" txt_f="12317">Patients with allergic rhinitis, </offsets><italic><offsets xml_i="18494" xml_f="18495" txt_i="12317" txt_f="12318">n</offsets></italic><offsets xml_i="18504" xml_f="18508" txt_i="12318" txt_f="12322"> (%)</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="18555" xml_f="18563" txt_i="12323" txt_f="12331">15 (100)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18618" xml_f="18673" txt_i="12332" txt_f="12387">Concomitant medication during the double blind period, </offsets><italic><offsets xml_i="18681" xml_f="18682" txt_i="12387" txt_f="12388">n</offsets></italic><offsets xml_i="18691" xml_f="18695" txt_i="12388" txt_f="12392"> (%)</offsets></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18783" xml_f="18801" txt_i="12394" txt_f="12412">Montelukast sodium</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="18848" xml_f="18855" txt_i="12413" txt_f="12420">1 (6.7)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18910" xml_f="18933" txt_i="12421" txt_f="12444">Inhaled corticosteroids</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="18980" xml_f="18988" txt_i="12445" txt_f="12453">5 (33.3)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19043" xml_f="19057" txt_i="12454" txt_f="12468">Antihistamines</offsets></td><td align="right" rowspan="1" colspan="1"><offsets xml_i="19104" xml_f="19112" txt_i="12469" txt_f="12477">2 (13.3)</offsets></td></tr></tbody></table></table-wrap><sec><title><offsets xml_i="19163" xml_f="19186" txt_i="12478" txt_f="12501">Spirometry Measurements</offsets></title><p><offsets xml_i="19197" xml_f="19232" txt_i="12502" txt_f="12537">The maximum percent decrease in FEV</offsets><sub><offsets xml_i="19237" xml_f="19238" txt_i="12537" txt_f="12538">1</offsets></sub><offsets xml_i="19244" xml_f="19442" txt_i="12538" txt_f="12736"> from visit postdose/pre-challenge (primary endpoint) was significantly less in patients treated with levalbuterol compared with placebo (LS mean ± SE: −4.8% ± 2.8% and −22.5% ± 2.8%, respectively; </offsets><italic><offsets xml_i="19450" xml_f="19451" txt_i="12736" txt_f="12737">p</offsets></italic><offsets xml_i="19460" xml_f="19472" txt_i="12737" txt_f="12749"> = 0.0002) (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="19504" xml_f="19513" txt_i="12749" txt_f="12758">Figure 1A</offsets></xref><offsets xml_i="19520" xml_f="19547" txt_i="12758" txt_f="12785">). The mean decrease in FEV</offsets><sub><offsets xml_i="19552" xml_f="19553" txt_i="12785" txt_f="12786">1</offsets></sub><offsets xml_i="19559" xml_f="19671" txt_i="12786" txt_f="12898"> from postdose/pre-challenge at each time point after exercise was also less for levalbuterol than for placebo (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="19703" xml_f="19711" txt_i="12898" txt_f="12906">Figure 2</offsets></xref><offsets xml_i="19718" xml_f="19839" txt_i="12906" txt_f="13027">). More patients were protected against EIB with levalbuterol than placebo. Only 1 of 15 (6.7%) patients (patient 2; see </offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="19873" xml_f="19880" txt_i="13027" txt_f="13034">Table 2</offsets></xref><offsets xml_i="19887" xml_f="19950" txt_i="13034" txt_f="13097">) treated with levalbuterol had a more than 20% decrease in FEV</offsets><sub><offsets xml_i="19955" xml_f="19956" txt_i="13097" txt_f="13098">1</offsets></sub><offsets xml_i="19962" xml_f="20015" txt_i="13098" txt_f="13151"> compared with 7 of 15 (46.7%) patients for placebo (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="20047" xml_f="20056" txt_i="13151" txt_f="13160">Figure 1B</offsets></xref><offsets xml_i="20063" xml_f="20159" txt_i="13160" txt_f="13256">). In contrast, 12 of 15 (80%) patients after levalbuterol use had less than 10% decrease in FEV</offsets><sub><offsets xml_i="20164" xml_f="20165" txt_i="13256" txt_f="13257">1</offsets></sub><offsets xml_i="20171" xml_f="20215" txt_i="13257" txt_f="13301"> compared with 2 of 15 (13.3%) for placebo (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="20247" xml_f="20256" txt_i="13301" txt_f="13310">Figure 1B</offsets></xref><offsets xml_i="20263" xml_f="20287" txt_i="13310" txt_f="13334">). The mean time for FEV</offsets><sub><offsets xml_i="20292" xml_f="20293" txt_i="13334" txt_f="13335">1</offsets></sub><offsets xml_i="20299" xml_f="20390" txt_i="13335" txt_f="13426"> recovery was faster with levalbuterol (15.0 minutes) compared with placebo (46.4 minutes).</offsets></p><fig id="fig1" position="float"><label><offsets xml_i="20433" xml_f="20441" txt_i="13427" txt_f="13435">Figure 1</offsets></label><caption><p><offsets xml_i="20461" xml_f="20496" txt_i="13435" txt_f="13470">(A) Maximum percent decrease in FEV</offsets><sub><offsets xml_i="20501" xml_f="20502" txt_i="13470" txt_f="13471">1</offsets></sub><offsets xml_i="20508" xml_f="20700" txt_i="13471" txt_f="13663"> for each patient from postdose/pre-challenge after treatment with placebo (DB-placebo) or levalbuterol (DB-levalbuterol) during the double-blind period for each patient. Patient numbers (see </offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="20734" xml_f="20741" txt_i="13663" txt_f="13670">Table 2</offsets></xref><offsets xml_i="20748" xml_f="20999" txt_i="13670" txt_f="13921">) are indicated and the solid grey lines are to aid following individual patient values. LS-mean (Least square mean) is the adjusted means for the effects in the model (see methods). (B) Percent of patients protected at 10%, 15%, and 20% is indicated.</offsets></p></caption><graphic xlink:href="ljas44-729-f1"></graphic></fig><fig id="fig2" position="float"><label><offsets xml_i="21104" xml_f="21112" txt_i="13922" txt_f="13930">Figure 2</offsets></label><caption><p><offsets xml_i="21132" xml_f="21144" txt_i="13930" txt_f="13942">The mean FEV</offsets><sub><offsets xml_i="21149" xml_f="21150" txt_i="13942" txt_f="13943">1</offsets></sub><offsets xml_i="21156" xml_f="21333" txt_i="13943" txt_f="14120"> predose, postdose/pre-exercise challenge, and at each time point post-exercise after treatment with levalbuterol or placebo. The standard deviation for each point is indicated.</offsets></p></caption><graphic xlink:href="ljas44-729-f2"></graphic></fig><table-wrap id="tbl2" position="float"><label><offsets xml_i="21445" xml_f="21452" txt_i="14121" txt_f="14128">Table 2</offsets></label><caption><p><offsets xml_i="21472" xml_f="21503" txt_i="14128" txt_f="14159">Maximum percent decrease in FEV</offsets><sub><offsets xml_i="21508" xml_f="21509" txt_i="14159" txt_f="14160">1</offsets></sub><offsets xml_i="21515" xml_f="21596" txt_i="14160" txt_f="14241"> after exercise from two different baselines: postdose/pre-challenge and predose.</offsets><xref ref-type="table-fn" rid="tf2-1"><offsets xml_i="21634" xml_f="21635" txt_i="14241" txt_f="14242">*</offsets></xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="21780" xml_f="21820" txt_i="14243" txt_f="14283">Visit postdose/pre-challenge at baseline</offsets></th><th colspan="3" align="center" rowspan="1"><offsets xml_i="21868" xml_f="21894" txt_i="14283" txt_f="14309">Visit pre-dose at baseline</offsets></th></tr><tr><th rowspan="1" colspan="1"></th><th colspan="3" align="center" rowspan="1"><hr></hr></th><th colspan="3" align="center" rowspan="1"><hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="22105" xml_f="22113" txt_i="14309" txt_f="14317">Patients</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="22161" xml_f="22186" txt_i="14317" txt_f="14342">Screening visit (placebo)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="22234" xml_f="22244" txt_i="14342" txt_f="14352">DB-placebo</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="22292" xml_f="22307" txt_i="14352" txt_f="14367">DB-levalbuterol</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="22355" xml_f="22380" txt_i="14367" txt_f="14392">Screening visit (placebo)</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="22428" xml_f="22438" txt_i="14392" txt_f="14402">DB-placebo</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="22486" xml_f="22501" txt_i="14402" txt_f="14417">DB-levalbuterol</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22571" xml_f="22572" txt_i="14417" txt_f="14418">1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22627" xml_f="22632" txt_i="14419" txt_f="14424">−42.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22687" xml_f="22692" txt_i="14425" txt_f="14430">−24.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22747" xml_f="22751" txt_i="14431" txt_f="14435">−0.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22806" xml_f="22811" txt_i="14436" txt_f="14441">−41.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22866" xml_f="22871" txt_i="14442" txt_f="14447">−25.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="22926" xml_f="22929" txt_i="14448" txt_f="14451">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22984" xml_f="22985" txt_i="14452" txt_f="14453">2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23040" xml_f="23045" txt_i="14454" txt_f="14459">−40.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23100" xml_f="23105" txt_i="14460" txt_f="14465">−54.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23160" xml_f="23165" txt_i="14466" txt_f="14471">−21.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23220" xml_f="23225" txt_i="14472" txt_f="14477">−40.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23280" xml_f="23285" txt_i="14478" txt_f="14483">−55.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23340" xml_f="23344" txt_i="14484" txt_f="14488">−1.5</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="23399" xml_f="23400" txt_i="14489" txt_f="14490">3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23455" xml_f="23460" txt_i="14491" txt_f="14496">−31.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23515" xml_f="23520" txt_i="14497" txt_f="14502">−31.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23575" xml_f="23579" txt_i="14503" txt_f="14507">−6.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23634" xml_f="23639" txt_i="14508" txt_f="14513">−31.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23694" xml_f="23699" txt_i="14514" txt_f="14519">−33.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23754" xml_f="23757" txt_i="14520" txt_f="14523">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="23812" xml_f="23813" txt_i="14524" txt_f="14525">4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23868" xml_f="23873" txt_i="14526" txt_f="14531">−30.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23928" xml_f="23933" txt_i="14532" txt_f="14537">−44.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="23988" xml_f="23992" txt_i="14538" txt_f="14542">−0.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24047" xml_f="24052" txt_i="14543" txt_f="14548">−28.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24107" xml_f="24112" txt_i="14549" txt_f="14554">−42.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24167" xml_f="24170" txt_i="14555" txt_f="14558">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="24225" xml_f="24226" txt_i="14559" txt_f="14560">5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24281" xml_f="24286" txt_i="14561" txt_f="14566">−27.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24341" xml_f="24346" txt_i="14567" txt_f="14572">−30.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24401" xml_f="24405" txt_i="14573" txt_f="14577">−4.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24460" xml_f="24465" txt_i="14578" txt_f="14583">−27.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24520" xml_f="24525" txt_i="14584" txt_f="14589">−29.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24580" xml_f="24583" txt_i="14590" txt_f="14593">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="24638" xml_f="24639" txt_i="14594" txt_f="14595">6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24694" xml_f="24699" txt_i="14596" txt_f="14601">−26.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24754" xml_f="24759" txt_i="14602" txt_f="14607">−16.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24814" xml_f="24819" txt_i="14608" txt_f="14613">−12.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24874" xml_f="24879" txt_i="14614" txt_f="14619">−27.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24934" xml_f="24939" txt_i="14620" txt_f="14625">−18.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="24994" xml_f="24998" txt_i="14626" txt_f="14630">−4.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25053" xml_f="25054" txt_i="14631" txt_f="14632">7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25109" xml_f="25114" txt_i="14633" txt_f="14638">−25.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25169" xml_f="25174" txt_i="14639" txt_f="14644">−20.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25229" xml_f="25233" txt_i="14645" txt_f="14649">−8.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25288" xml_f="25293" txt_i="14650" txt_f="14655">−26.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25348" xml_f="25353" txt_i="14656" txt_f="14661">−20.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25408" xml_f="25411" txt_i="14662" txt_f="14665">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25466" xml_f="25467" txt_i="14666" txt_f="14667">8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25522" xml_f="25527" txt_i="14668" txt_f="14673">−23.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25582" xml_f="25587" txt_i="14674" txt_f="14679">−16.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25642" xml_f="25646" txt_i="14680" txt_f="14684">−7.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25701" xml_f="25706" txt_i="14685" txt_f="14690">−21.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25761" xml_f="25766" txt_i="14691" txt_f="14696">−17.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25821" xml_f="25825" txt_i="14697" txt_f="14701">−5.7</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="25880" xml_f="25881" txt_i="14702" txt_f="14703">9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25936" xml_f="25941" txt_i="14704" txt_f="14709">−23.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="25996" xml_f="25999" txt_i="14710" txt_f="14713">0.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26054" xml_f="26057" txt_i="14714" txt_f="14717">0.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26112" xml_f="26117" txt_i="14718" txt_f="14723">−24.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26172" xml_f="26175" txt_i="14724" txt_f="14727">0.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26230" xml_f="26233" txt_i="14728" txt_f="14731">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26288" xml_f="26290" txt_i="14732" txt_f="14734">10</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26345" xml_f="26350" txt_i="14735" txt_f="14740">−22.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26405" xml_f="26410" txt_i="14741" txt_f="14746">−24.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26465" xml_f="26469" txt_i="14747" txt_f="14751">−4.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26524" xml_f="26529" txt_i="14752" txt_f="14757">−21.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26584" xml_f="26589" txt_i="14758" txt_f="14763">−20.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26644" xml_f="26647" txt_i="14764" txt_f="14767">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="26702" xml_f="26704" txt_i="14768" txt_f="14770">11</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26759" xml_f="26764" txt_i="14771" txt_f="14776">−21.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26819" xml_f="26823" txt_i="14777" txt_f="14781">−8.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26878" xml_f="26883" txt_i="14782" txt_f="14787">−10.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26938" xml_f="26943" txt_i="14788" txt_f="14793">−22.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="26998" xml_f="27002" txt_i="14794" txt_f="14798">−7.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27057" xml_f="27061" txt_i="14799" txt_f="14803">−5.3</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27116" xml_f="27118" txt_i="14804" txt_f="14806">12</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27173" xml_f="27178" txt_i="14807" txt_f="14812">−21.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27233" xml_f="27238" txt_i="14813" txt_f="14818">−14.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27293" xml_f="27297" txt_i="14819" txt_f="14823">−0.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27352" xml_f="27357" txt_i="14824" txt_f="14829">−20.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27412" xml_f="27417" txt_i="14830" txt_f="14835">−15.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27472" xml_f="27475" txt_i="14836" txt_f="14839">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27530" xml_f="27532" txt_i="14840" txt_f="14842">13</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27587" xml_f="27592" txt_i="14843" txt_f="14848">−20.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27647" xml_f="27652" txt_i="14849" txt_f="14854">−17.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27707" xml_f="27710" txt_i="14855" txt_f="14858">0.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27765" xml_f="27770" txt_i="14859" txt_f="14864">−16.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27825" xml_f="27830" txt_i="14865" txt_f="14870">−18.3</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="27885" xml_f="27888" txt_i="14871" txt_f="14874">0.0</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="27943" xml_f="27945" txt_i="14875" txt_f="14877">14</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28000" xml_f="28005" txt_i="14878" txt_f="14883">−22.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28060" xml_f="28065" txt_i="14884" txt_f="14889">−11.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28120" xml_f="28124" txt_i="14890" txt_f="14894">−4.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28179" xml_f="28184" txt_i="14895" txt_f="14900">−20.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28239" xml_f="28243" txt_i="14901" txt_f="14905">−8.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28298" xml_f="28302" txt_i="14906" txt_f="14910">−0.6</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28357" xml_f="28359" txt_i="14911" txt_f="14913">15</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28414" xml_f="28419" txt_i="14914" txt_f="14919">−19.0</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28474" xml_f="28479" txt_i="14920" txt_f="14925">−12.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28534" xml_f="28538" txt_i="14926" txt_f="14930">−5.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28593" xml_f="28598" txt_i="14931" txt_f="14936">−19.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28653" xml_f="28658" txt_i="14937" txt_f="14942">−13.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28713" xml_f="28717" txt_i="14943" txt_f="14947">−2.5</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="28772" xml_f="28781" txt_i="14948" txt_f="14957">Mean (SD)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28836" xml_f="28847" txt_i="14958" txt_f="14969">−26.5 (7.0)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28902" xml_f="28914" txt_i="14970" txt_f="14982">−21.8 (14.0)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="28969" xml_f="28979" txt_i="14983" txt_f="14993">−5.8 (5.8)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="29034" xml_f="29045" txt_i="14994" txt_f="15005">−26.0 (7.3)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="29100" xml_f="29112" txt_i="15006" txt_f="15018">−21.8 (14.2)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="29167" xml_f="29177" txt_i="15019" txt_f="15029">−1.3 (2.1)</offsets></td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><label><offsets xml_i="29242" xml_f="29243" txt_i="15030" txt_f="15031">*</offsets></label><p><offsets xml_i="29254" xml_f="29392" txt_i="15031" txt_f="15169">DB-placebo and DB-levalbuterol indicates the placebo or levalbuterol treatment, respectively, during the double-blind period of the study.</offsets></p></fn></table-wrap-foot></table-wrap><p><offsets xml_i="29435" xml_f="29579" txt_i="15170" txt_f="15314">Levalbuterol was associated with significantly greater bronchodilation before exercise compared with placebo. LS mean (SE) percent change in FEV</offsets><sub><offsets xml_i="29584" xml_f="29585" txt_i="15314" txt_f="15315">1</offsets></sub><offsets xml_i="29591" xml_f="29699" txt_i="15315" txt_f="15423"> from predose to postdose/pre-challenge was 9.4 ± 1.1 for levalbuterol compared with 0.3 ± 1.1 for placebo (</offsets><italic><offsets xml_i="29707" xml_f="29708" txt_i="15423" txt_f="15424">p</offsets></italic><offsets xml_i="29717" xml_f="29816" txt_i="15424" txt_f="15520"> &lt; 0.0001). After exercise following levalbuterol treatment, the maximum percent decrease in FEV</offsets><sub><offsets xml_i="29821" xml_f="29822" txt_i="15520" txt_f="15521">1</offsets></sub><offsets xml_i="29828" xml_f="29921" txt_i="15521" txt_f="15614"> values for the majority (9 of 15) of individual patients did not fall below predose levels (</offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="29955" xml_f="29962" txt_i="15614" txt_f="15621">Table 2</offsets></xref><offsets xml_i="29969" xml_f="29994" txt_i="15621" txt_f="15646">). Moreover, the mean FEV</offsets><sub><offsets xml_i="29999" xml_f="30000" txt_i="15646" txt_f="15647">1</offsets></sub><offsets xml_i="30006" xml_f="30042" txt_i="15647" txt_f="15683"> did not fall below predose levels (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="30074" xml_f="30082" txt_i="15683" txt_f="15691">Figure 2</offsets></xref><offsets xml_i="30089" xml_f="30183" txt_i="15691" txt_f="15785">). In contrast after exercise following placebo treatment, the maximum percent decrease in FEV</offsets><sub><offsets xml_i="30188" xml_f="30189" txt_i="15785" txt_f="15786">1</offsets></sub><offsets xml_i="30195" xml_f="30270" txt_i="15786" txt_f="15861"> values for the majority (14 of 15) of patients fell below predose values (</offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="30304" xml_f="30311" txt_i="15861" txt_f="15868">Table 2</offsets></xref><offsets xml_i="30318" xml_f="30348" txt_i="15868" txt_f="15898">). Post-exercise, the mean FEV</offsets><sub><offsets xml_i="30353" xml_f="30354" txt_i="15898" txt_f="15899">1</offsets></sub><offsets xml_i="30360" xml_f="30471" txt_i="15899" txt_f="16010"> after placebo treatment dropped below predose values. The LS mean (SE) for the maximum percent decrease in FEV</offsets><sub><offsets xml_i="30476" xml_f="30477" txt_i="16010" txt_f="16011">1</offsets></sub><offsets xml_i="30483" xml_f="30572" txt_i="16011" txt_f="16100"> from predose to postexercise was 9.8 ± 2.2 for levalbuterol and −4.2 ± 2.2 for placebo (</offsets><italic><offsets xml_i="30580" xml_f="30581" txt_i="16100" txt_f="16101">p</offsets></italic><offsets xml_i="30590" xml_f="30601" txt_i="16101" txt_f="16112"> = 0.0008).</offsets></p><p><offsets xml_i="30608" xml_f="30727" txt_i="16113" txt_f="16232">There was some intrapatient variability in response to exercise challenge. For a number of patients, the changes in FEV</offsets><sub><offsets xml_i="30732" xml_f="30733" txt_i="16232" txt_f="16233">1</offsets></sub><offsets xml_i="30739" xml_f="30855" txt_i="16233" txt_f="16349"> post-exercise for the two placebo treatments (at screening [visit 1] and the double-blind period) were dissimilar (</offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="30889" xml_f="30896" txt_i="16349" txt_f="16356">Table 2</offsets></xref><offsets xml_i="30903" xml_f="30905" txt_i="16356" txt_f="16358">).</offsets></p><p><offsets xml_i="30912" xml_f="31278" txt_i="16359" txt_f="16725">After placebo treatment, three patients required one dose of rescue medication after exercise challenge during the double-blind period of the study, and no patients required rescue medication after levalbuterol treatment. There was no significant difference in heart rate or respiration rates with levalbuterol and placebo treatments after exercise (data not shown).</offsets></p></sec><sec><title><offsets xml_i="31300" xml_f="31314" txt_i="16727" txt_f="16741">Adverse Events</offsets></title><p><offsets xml_i="31325" xml_f="31456" txt_i="16742" txt_f="16873">There were four adverse events observed. The reported post-randomization adverse events after levalbuterol treatment were myalgia (</offsets><italic><offsets xml_i="31464" xml_f="31465" txt_i="16873" txt_f="16874">n</offsets></italic><offsets xml_i="31474" xml_f="31494" txt_i="16874" txt_f="16894"> = 2) and vomiting (</offsets><italic><offsets xml_i="31502" xml_f="31503" txt_i="16894" txt_f="16895">n</offsets></italic><offsets xml_i="31512" xml_f="31564" txt_i="16895" txt_f="16947"> = 1), and after placebo treatment nasopharyngitis (</offsets><italic><offsets xml_i="31572" xml_f="31573" txt_i="16947" txt_f="16948">n</offsets></italic></p></sec></sec><sec><title><offsets xml_i="31610" xml_f="31620" txt_i="16951" txt_f="16961">Discussion</offsets></title><p><offsets xml_i="31631" xml_f="31877" txt_i="16962" txt_f="17208">We examined the ability of levalbuterol HFA 90 μg administered through an MDI to protect adults with asthma from EIB. Levalbuterol HFA taken 30 minutes before treadmill exercise was found to be protective. The mean maximum percent decrease in FEV</offsets><sub><offsets xml_i="31882" xml_f="31883" txt_i="17208" txt_f="17209">1</offsets></sub><offsets xml_i="31889" xml_f="31964" txt_i="17209" txt_f="17284"> from postdose/pre-challenge (primary endpoint) was significantly smaller (</offsets><italic><offsets xml_i="31972" xml_f="31973" txt_i="17284" txt_f="17285">p</offsets></italic><offsets xml_i="31982" xml_f="32143" txt_i="17285" txt_f="17443"> &lt; 0.001) for levalbuterol treatment than for placebo. All but 1 of 15 subjects were protected from EIB when using levalbuterol with a maximum decrease in FEV</offsets><sub><offsets xml_i="32148" xml_f="32149" txt_i="17443" txt_f="17444">1</offsets></sub><offsets xml_i="32155" xml_f="32232" txt_i="17444" txt_f="17521"> of less than 20%, a criteria suggested by the USDHHS Guidance for Industry (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="32264" xml_f="32266" txt_i="17521" txt_f="17523">17</offsets></xref><offsets xml_i="32273" xml_f="32304" txt_i="17523" txt_f="17554">). Although the decrease in FEV</offsets><sub><offsets xml_i="32309" xml_f="32310" txt_i="17554" txt_f="17555">1</offsets></sub><offsets xml_i="32316" xml_f="32491" txt_i="17555" txt_f="17730"> was greater than 20% for one patient (patient #2), this patient still had a large degree of protection from EIB after levalbuterol treatment, (maximum percent decrease in FEV</offsets><sub><offsets xml_i="32496" xml_f="32497" txt_i="17730" txt_f="17731">1</offsets></sub><offsets xml_i="32503" xml_f="32585" txt_i="17731" txt_f="17813"> following DB-Placebo was −54.1% compared with −21.3% following DB-Levalbuterol) (</offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="32619" xml_f="32626" txt_i="17813" txt_f="17820">Table 2</offsets></xref><offsets xml_i="32633" xml_f="32689" txt_i="17820" txt_f="17876">). The fact that levalbuterol improved post-exercise FEV</offsets><sub><offsets xml_i="32694" xml_f="32695" txt_i="17876" txt_f="17877">1</offsets></sub><offsets xml_i="32701" xml_f="32828" txt_i="17877" txt_f="18004"> by 32.8% but the decrease was still greater than 20% may reflect the very low baseline value for this patient (decrease in FEV</offsets><sub><offsets xml_i="32833" xml_f="32834" txt_i="18004" txt_f="18005">1</offsets></sub><offsets xml_i="32840" xml_f="32952" txt_i="18005" txt_f="18117"> after DB-Placebo treatment). All other measurements of pulmonary function, including mean percent change in FEV</offsets><sub><offsets xml_i="32957" xml_f="32958" txt_i="18117" txt_f="18118">1</offsets></sub><offsets xml_i="32964" xml_f="33013" txt_i="18118" txt_f="18167"> at all time points post-exercise and time to FEV</offsets><sub><offsets xml_i="33018" xml_f="33019" txt_i="18167" txt_f="18168">1</offsets></sub><offsets xml_i="33025" xml_f="33269" txt_i="18168" txt_f="18412"> recovery (baseline), were supportive of the effective protection against EIB by levalbuterol. None of the three instances in which rescue medication related to exercise challenges was required occurred when levalbuterol was used pre-challenge.</offsets></p><p><offsets xml_i="33276" xml_f="33465" txt_i="18413" txt_f="18602">The degree of protection from EIB can be considered clinically important. After levalbuterol treatment, the majority of patients were protected (12 of 15 had less than a 10% decrease in FEV</offsets><sub><offsets xml_i="33470" xml_f="33471" txt_i="18602" txt_f="18603">1</offsets></sub><offsets xml_i="33477" xml_f="33663" txt_i="18603" txt_f="18789"> and 14 of 15 had less than a 15% decrease after exercise). In contrast after placebo treatment, most patients were not protected against EIB (2 of 15 had less than a 10% decrease in FEV</offsets><sub><offsets xml_i="33668" xml_f="33669" txt_i="18789" txt_f="18790">1</offsets></sub><offsets xml_i="33675" xml_f="33752" txt_i="18790" txt_f="18867"> and 5 of 15 had less than 15% decrease post-exercise). A 10% decrease in FEV</offsets><sub><offsets xml_i="33757" xml_f="33758" txt_i="18867" txt_f="18868">1</offsets></sub><offsets xml_i="33764" xml_f="33831" txt_i="18868" txt_f="18935"> is considered to be indicative of healthy non-asthmatic subjects (</offsets><xref ref-type="bibr" rid="b18"><offsets xml_i="33863" xml_f="33865" txt_i="18935" txt_f="18937">18</offsets></xref><offsets xml_i="33872" xml_f="33874" txt_i="18937" txt_f="18939">, </offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="33906" xml_f="33908" txt_i="18939" txt_f="18941">21</offsets></xref><offsets xml_i="33915" xml_f="33916" txt_i="18941" txt_f="18942">–</offsets><xref ref-type="bibr" rid="b23"><offsets xml_i="33948" xml_f="33950" txt_i="18942" txt_f="18944">23</offsets></xref><offsets xml_i="33957" xml_f="33994" txt_i="18944" txt_f="18981">), while a 15% or greater fall in FEV</offsets><sub><offsets xml_i="33999" xml_f="34000" txt_i="18981" txt_f="18982">1</offsets></sub><offsets xml_i="34006" xml_f="34080" txt_i="18982" txt_f="19056"> is considered by some investigators and guidelines as a diagnosis of EIB.</offsets></p><p><offsets xml_i="34087" xml_f="34270" txt_i="19057" txt_f="19240">Protection by levalbuterol was also associated with a rapid bronchodilating effect achieved pre-exercise challenge. Although postdose/pre-challenge has been a commonly used baseline (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="34302" xml_f="34304" txt_i="19240" txt_f="19242">17</offsets></xref><offsets xml_i="34311" xml_f="34379" txt_i="19242" txt_f="19310">), others have suggested predose to be a more appropriate baseline (</offsets><xref ref-type="bibr" rid="b24"><offsets xml_i="34411" xml_f="34413" txt_i="19310" txt_f="19312">24</offsets></xref><offsets xml_i="34420" xml_f="34422" txt_i="19312" txt_f="19314">, </offsets><xref ref-type="bibr" rid="b25"><offsets xml_i="34454" xml_f="34456" txt_i="19314" txt_f="19316">25</offsets></xref><offsets xml_i="34463" xml_f="34816" txt_i="19316" txt_f="19669">). However, with the exception of one patient, in this study, the degree of bronchodilation after exercise from postdose/pre-challenge was not sufficiently different from predose to alter the conclusions of the study if predose was used for baseline (data not shown). The duration of the protective effect of levalbuterol was not examined in this study.</offsets></p><p><offsets xml_i="34823" xml_f="34953" txt_i="19670" txt_f="19800">Asthma is characterized by differences between patients and by intrapatient variability both over short and long periods of time (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="34985" xml_f="34987" txt_i="19800" txt_f="19802">17</offsets></xref><offsets xml_i="34994" xml_f="35103" txt_i="19802" txt_f="19911">). In this study, variability in a patient's response was apparent by the difference in percent change in FEV</offsets><sub><offsets xml_i="35108" xml_f="35109" txt_i="19911" txt_f="19912">1</offsets></sub><offsets xml_i="35115" xml_f="35179" txt_i="19912" txt_f="19976"> between the screening and the double-blind placebo treatments (</offsets><xref ref-type="table" rid="tbl2"><offsets xml_i="35213" xml_f="35220" txt_i="19976" txt_f="19983">Table 2</offsets></xref><offsets xml_i="35227" xml_f="35568" txt_i="19983" txt_f="20324">). In this context, prescribing physicians as well as patients need to appreciate the potential variability in degree of protection by a single dose of bronchoprotective agents used before exercise. Moreover, consistent (e.g., daily) use of β-adrenergic agents can lead to relative tolerance to the bronchoprotective effect of these agents (</offsets><xref ref-type="bibr" rid="b15"><offsets xml_i="35600" xml_f="35602" txt_i="20324" txt_f="20326">15</offsets></xref><offsets xml_i="35609" xml_f="35611" txt_i="20326" txt_f="20328">, </offsets><xref ref-type="bibr" rid="b26"><offsets xml_i="35643" xml_f="35645" txt_i="20328" txt_f="20330">26</offsets></xref><offsets xml_i="35652" xml_f="35653" txt_i="20330" txt_f="20331">–</offsets><xref ref-type="bibr" rid="b29"><offsets xml_i="35685" xml_f="35687" txt_i="20331" txt_f="20333">29</offsets></xref><offsets xml_i="35694" xml_f="35768" txt_i="20333" txt_f="20407">), although intervals of use of 72 hours or greater abrogate this effect (</offsets><xref ref-type="bibr" rid="b28"><offsets xml_i="35800" xml_f="35802" txt_i="20407" txt_f="20409">28</offsets></xref><offsets xml_i="35809" xml_f="35937" txt_i="20409" txt_f="20537">). Long-term anti-inflammatory control of asthma can decrease bronchial reactivity to various asthma triggers such as exercise (</offsets><xref ref-type="bibr" rid="b30"><offsets xml_i="35969" xml_f="35971" txt_i="20537" txt_f="20539">30</offsets></xref><offsets xml_i="35978" xml_f="35979" txt_i="20539" txt_f="20540">–</offsets><xref ref-type="bibr" rid="b33"><offsets xml_i="36011" xml_f="36013" txt_i="20540" txt_f="20542">33</offsets></xref><offsets xml_i="36020" xml_f="36022" txt_i="20542" txt_f="20544">).</offsets></p><sec><title><offsets xml_i="36038" xml_f="36048" txt_i="20545" txt_f="20555">Conclusion</offsets></title><p><offsets xml_i="36059" xml_f="36335" txt_i="20556" txt_f="20832">This is the first reported evaluation of the ability of levalbuterol HFA MDI used as single dose pre-treatment to protect patients from EIB. It was found that a single dose administered 30 minutes before exercise was effective in protecting against EIB and was well tolerated.</offsets></p></sec></sec></body><back><ack><p>The authors would like to thank E. Goodwin, Ph.D., of Sepracor for her assistance in the preparation of the manuscript.</p></ack><ref-list><title>REFERENCES</title><ref id="b1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JP</given-names></name><name><surname>Mastronarde</surname><given-names>JG</given-names></name></person-group><article-title>Exercise-induced bronchoconstriction in athletes</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>3966</fpage><lpage>3974</lpage><pub-id pub-id-type="pmid">16354868</pub-id></citation></ref><ref id="b2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SD</given-names></name><name><surname>Caillaud</surname><given-names>C</given-names></name><name><surname>Brannan</surname><given-names>JD</given-names></name></person-group><article-title>Beta2-agonists and exercise-induced asthma</article-title><source>Clin Rev Allergy Immunol</source><year>2006</year><volume>31</volume><fpage>163</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">17085791</pub-id></citation></ref><ref id="b3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>CJ</given-names></name><name><surname>Cochrane</surname><given-names>LM</given-names></name></person-group><article-title>Physical activity and asthma</article-title><source>Curr Opin Pulm Med</source><year>1999</year><volume>5</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">10813253</pub-id></citation></ref><ref id="b4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Kroner-Herwig</surname><given-names>B</given-names></name><name><surname>Sporkel</surname><given-names>H</given-names></name></person-group><article-title>The effect of exercise and induced expectations on visceral perception in asthmatic patients</article-title><source>J Psychosom Res</source><year>1990</year><volume>34</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">2376845</pub-id></citation></ref><ref id="b5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ergood</surname><given-names>JS</given-names></name><name><surname>Epstein</surname><given-names>LH</given-names></name><name><surname>Ackerman</surname><given-names>M</given-names></name><name><surname>Fireman</surname><given-names>P</given-names></name></person-group><article-title>Perception of expiratory flow by asthmatics and non-asthmatics during rest and exercise</article-title><source>Health Psychol</source><year>1985</year><volume>4</volume><fpage>545</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">3830704</pub-id></citation></ref><ref id="b6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panditi</surname><given-names>S</given-names></name><name><surname>Silverman</surname><given-names>M</given-names></name></person-group><article-title>Perception of exercise induced asthma by children and their parents</article-title><source>Arch Dis Child</source><year>2003</year><volume>88</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">12937106</pub-id></citation></ref><ref id="b7"><label>7</label><citation citation-type="book"><collab>NHLBI</collab><article-title>Guidelines for the diagnosis and management of asthma</article-title><year>1997</year><publisher-name>National Institutes of Health</publisher-name><comment>Report: 97-4051</comment></citation></ref><ref id="b8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Penn</surname><given-names>RB</given-names></name><name><surname>Frielle</surname><given-names>T</given-names></name><name><surname>McCullough</surname><given-names>JR</given-names></name><name><surname>Aberg</surname><given-names>G</given-names></name><name><surname>Benovic</surname><given-names>JL</given-names></name></person-group><article-title>Comparison of R-, S-, and RS-albuterol interaction with human beta 1-and beta 2adrenergic receptors</article-title><source>Clin Rev Allergy Immunol</source><year>1996</year><volume>14</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">8866170</pub-id></citation></ref><ref id="b9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lotvall</surname><given-names>J</given-names></name><name><surname>Palmqvist</surname><given-names>M</given-names></name><name><surname>Arvidsson</surname><given-names>P</given-names></name><name><surname>Maloney</surname><given-names>A</given-names></name><name><surname>Ventresca</surname><given-names>GP</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name></person-group><article-title>The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients</article-title><source>J Allergy Clin Immunol</source><year>2001</year><volume>108</volume><fpage>726</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">11692096</pub-id></citation></ref><ref id="b10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milgrom</surname><given-names>H</given-names></name></person-group><article-title>Levosalbutamol in the treatment of asthma</article-title><source>Expert Opin Pharmacother</source><year>2006</year><volume>7</volume><fpage>1659</fpage><lpage>1668</lpage><pub-id pub-id-type="pmid">16872269</pub-id></citation></ref><ref id="b11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berkowitz</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>E</given-names></name><name><surname>Bukstein</surname><given-names>D</given-names></name><name><surname>Grunstein</surname><given-names>M</given-names></name><name><surname>Chai</surname><given-names>H</given-names></name></person-group><article-title>Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate</article-title><source>Pediatrics</source><year>1986</year><volume>77</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">3945530</pub-id></citation></ref><ref id="b12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawksworth</surname><given-names>RJ</given-names></name><name><surname>Sykes</surname><given-names>AP</given-names></name><name><surname>Faris</surname><given-names>M</given-names></name><name><surname>Mant</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name></person-group><article-title>Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction</article-title><source>Ann Allergy Asthma Immunol</source><year>2002</year><volume>88</volume><fpage>473</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">12027068</pub-id></citation></ref><ref id="b13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>GS</given-names></name><name><surname>Yegen</surname><given-names>U</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Kottakis</surname><given-names>J</given-names></name><name><surname>Della</surname><given-names>CG</given-names></name></person-group><article-title>A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol</article-title><source>Clin Ther</source><year>2002</year><volume>24</volume><fpage>2077</fpage><lpage>2087</lpage><pub-id pub-id-type="pmid">12581546</pub-id></citation></ref><ref id="b14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sichletidis</surname><given-names>L</given-names></name><name><surname>Daskalopoulou</surname><given-names>E</given-names></name><name><surname>Kyriazis</surname><given-names>G</given-names></name><name><surname>Kosmidou</surname><given-names>I</given-names></name><name><surname>Koupidou</surname><given-names>S</given-names></name><name><surname>Pechlivanidis</surname><given-names>T</given-names></name><name><surname>Chloros</surname><given-names>D</given-names></name></person-group><article-title>Comparative efficacy of salbutamol and salmeterol in exercise-induced asthma</article-title><source>J Int Med Res</source><year>1993</year><volume>21</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">8243793</pub-id></citation></ref><ref id="b15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inman</surname><given-names>M</given-names></name><name><surname>O'Byrne</surname><given-names>P</given-names></name></person-group><article-title>The effect of regular inhaled albuterol on exercise-induced bronchoconstriction</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>153</volume><fpage>65</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">8542164</pub-id></citation></ref><ref id="b16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crapo</surname><given-names>RO</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Coates</surname><given-names>AL</given-names></name><name><surname>Enright</surname><given-names>PL</given-names></name><name><surname>Hankinson</surname><given-names>JL</given-names></name><name><surname>Irvin</surname><given-names>CG</given-names></name><name><surname>MacIntyre</surname><given-names>NR</given-names></name><name><surname>McKay</surname><given-names>RT</given-names></name><name><surname>Wanger</surname><given-names>JS</given-names></name><name><surname>Anderson</surname><given-names>SD</given-names></name><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Fish</surname><given-names>JE</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name></person-group><article-title>Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, 1999</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><fpage>309</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">10619836</pub-id></citation></ref><ref id="b17"><label>17</label><citation citation-type="other"><collab>U.S. Department of Health and Human Services FC</collab><article-title>Guidance for Industry;Exercise-induced bronchospasm (EIB)—development of drugs to prevent EIB (draft)</article-title><year>2002</year></citation></ref><ref id="b18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McFadden</surname><given-names>ER</given-names><suffix>Jr</suffix></name><name><surname>Gilbert</surname><given-names>IA</given-names></name></person-group><article-title>Exercise-induced asthma</article-title><source>N Engl J Med</source><year>1994</year><volume>12</volume><issue>330</issue><fpage>1362</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">8152449</pub-id></citation></ref><ref id="b19"><label>19</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Kenward</surname><given-names>M</given-names></name></person-group><source>Design and analysis of cross-over trials (monographs on statistics and applied probability)</source><year>2003</year><edition>2nd ed.</edition><publisher-loc>Boca Raton, FL</publisher-loc><publisher-name>Chapman &amp; Hall</publisher-name></citation></ref><ref id="b20"><label>20</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Littell</surname><given-names>RC</given-names></name><name><surname>Milliken</surname><given-names>GA</given-names></name><name><surname>Stroup</surname><given-names>WW</given-names></name><name><surname>Wolfinger</surname><given-names>RD</given-names></name></person-group><source>SAS systems for mixed models</source><year>1996</year><publisher-loc>Cary, NC</publisher-loc><publisher-name>SAS Publishing</publisher-name></citation></ref><ref id="b21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Quanjer</surname><given-names>PH</given-names></name><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>O'Byrne</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>SD</given-names></name><name><surname>Juniper</surname><given-names>EF</given-names></name><name><surname>Malo</surname><given-names>JL</given-names></name></person-group><article-title>Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society</article-title><source>Eur Respir J Suppl</source><year>1993</year><volume>16</volume><fpage>53</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8499055</pub-id></citation></ref><ref id="b22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SD</given-names></name><name><surname>Lambert</surname><given-names>S</given-names></name><name><surname>Brannan</surname><given-names>JD</given-names></name><name><surname>Wood</surname><given-names>RJ</given-names></name><name><surname>Koskela</surname><given-names>H</given-names></name><name><surname>Morton</surname><given-names>AR</given-names></name><name><surname>Fitch</surname><given-names>KD</given-names></name></person-group><article-title>Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices</article-title><source>Med Sci Sports Exerc</source><year>2001</year><volume>33</volume><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">11404653</pub-id></citation></ref><ref id="b23"><label>23</label><citation citation-type="journal"><collab>Task force on recognizing and diagnosing exercise-related asthma, respiratory and allergic disorder in sports</collab><article-title>Evidence-based recommendations for the diagnosis of exercise-induced asthma in athletes</article-title><source>Eur Respir Mon</source><year>2005</year><volume>33</volume><fpage>102</fpage><lpage>104</lpage></citation></ref><ref id="b24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group><article-title>The use of baselines in clinical trials of bronchodilators</article-title><source>Stat Med</source><year>1989</year><volume>8</volume><fpage>1339</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">2692110</pub-id></citation></ref><ref id="b25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boner</surname><given-names>AL</given-names></name><name><surname>Spezia</surname><given-names>E</given-names></name><name><surname>Piovesan</surname><given-names>P</given-names></name><name><surname>Chiocca</surname><given-names>E</given-names></name><name><surname>Maiocchi</surname><given-names>G</given-names></name></person-group><article-title>Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children</article-title><source>Am J Respir Crit Care Med</source><year>1994</year><volume>149</volume><issue>4 Pt 1</issue><fpage>935</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">7908246</pub-id></citation></ref><ref id="b26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>M</given-names></name></person-group><article-title>Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation</article-title><source>J Allergy Clin Immunol</source><year>2006</year><volume>117</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">16387578</pub-id></citation></ref><ref id="b27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hancox</surname><given-names>RJ</given-names></name><name><surname>Subbarao</surname><given-names>P</given-names></name><name><surname>Kamada</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>RM</given-names></name><name><surname>Hargreave</surname><given-names>FE</given-names></name><name><surname>Inman</surname><given-names>MD</given-names></name></person-group><article-title>Beta2-agonist tolerance and exercise-induced bronchospasm</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>1068</fpage><lpage>1070</lpage><pub-id pub-id-type="pmid">11956046</pub-id></citation></ref><ref id="b28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haney</surname><given-names>S</given-names></name><name><surname>Hancox</surname><given-names>RJ</given-names></name></person-group><article-title>Rapid onset of tolerance to beta-agonist bronchodilation</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">15823453</pub-id></citation></ref><ref id="b29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>MJ</given-names></name><name><surname>Qing</surname><given-names>F</given-names></name><name><surname>Rhodes</surname><given-names>CG</given-names></name><name><surname>Rahman</surname><given-names>SU</given-names></name><name><surname>Ind</surname><given-names>PW</given-names></name><name><surname>Sriskandan</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>T</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name></person-group><article-title>In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><fpage>1277</fpage><lpage>1283</lpage><pub-id pub-id-type="pmid">8912736</pub-id></citation></ref><ref id="b30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>SD</given-names></name></person-group><article-title>Single-dose agents in the prevention of exercise-induced asthma: a descriptive review</article-title><source>Treat Respir Med</source><year>2004</year><volume>3</volume><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">15658883</pub-id></citation></ref><ref id="b31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vathenen</surname><given-names>AS</given-names></name><name><surname>Knox</surname><given-names>AJ</given-names></name><name><surname>Wisniewski</surname><given-names>A</given-names></name><name><surname>Tattersfield</surname><given-names>AE</given-names></name></person-group><article-title>Effect of inhaled budesonide on bronchial reactivity to histamine, exercise, and eucapnic dry air hyperventilation in patients with asthma</article-title><source>Thorax</source><year>1991</year><volume>46</volume><fpage>811</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">1771604</pub-id></citation></ref><ref id="b32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vidal</surname><given-names>C</given-names></name><name><surname>Fernandez-Ovide</surname><given-names>E</given-names></name><name><surname>Pineiro</surname><given-names>J</given-names></name><name><surname>Nunez</surname><given-names>R</given-names></name><name><surname>Gonzalez-Quintela</surname><given-names>A</given-names></name></person-group><article-title>Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction</article-title><source>Ann Allergy Asthma Immunol</source><year>2001</year><volume>86</volume><fpage>655</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">11428738</pub-id></citation></ref><ref id="b33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>OR</given-names></name></person-group><article-title>Budesonide treatment of moderate and severe asthma in children: a dose-response study</article-title><source>J Allergy Clin Immunol</source><year>1995</year><volume>95</volume><issue>1 Pt 1</issue><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">7822661</pub-id></citation></ref></ref-list></back></article>